Journal
CANCER INVESTIGATION
Volume 30, Issue 1, Pages 48-56Publisher
INFORMA HEALTHCARE
DOI: 10.3109/07357907.2011.630050
Keywords
Signal transduction; Therapy; GBM
Categories
Funding
- National Institutes of Health (NIH) [R21CA133604, R01CA138701]
- William and Ella Owens Medical Research Foundation
- Vivian L. Smith Department of Neurosurgery at the University of Texas Health Science Center at Houston, Medical School
- NATIONAL CANCER INSTITUTE [R01CA138701, R21CA133604] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) is the most malignant and aggressive type of brain tumor with an average life expectancy of less than 15 months. This is mostly due to the highly mutated genome of GBM, which is characterized by the deregulation of many key signaling pathways involving growth, proliferation, survival, and apoptosis. It is critical to explore novel diagnostic and therapeutic strategies that target these pathways to improve the treatment of malignant glioma in the future. This review summarizes the most common and important pathways that are highly mutated or deregulated in GBM and discusses potential therapeutic strategies targeting these pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
